The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
Open accessAbstract
Background: Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2. This study tested the efficacy of baricitinib versus placebo on albuminuria in adults with Type 2 diabetes at high risk for progressive DKD. Methods: In this Phase 2, double-blind, dose-ranging study, participants were randomized 1:1:1:1:1 to receive placebo or baricitinib (0.75 mg daily; 0.75 mg twice daily; 1.5 mg daily; or 4 mg daily), for 24 weeks followed by 4-8 weeks of washout. Results: Participants (N = 129) were 63±9.1 (mean±standard deviation) years of age, 27.1% (35/129) women and 11.6% (15/129) African-American race. Baseline hemoglobin A1c (HbA1c) was 7.3±1% and estimated glomerular filtration rate was 45.0±12.1 mL/min/1.73 m2 with first morning urine albumin-creatinine ratio (UACR) of 820 (407-1632) (median; interquartile range) mg/g. Baricitinib, 4 mg daily, decreased morning UACR by 41% at Week 24 compared with placebo (ratio to baseline 0.59, 95% confidence interval 0.38-0.93, P = 0.022). UACR was decreased at Weeks 12 and 24 and after 4-8 weeks of washout. Baricitinib 4 mg decreased inflammatory biomarkers over 24 weeks (urine C-X-C motif chemokine 10 and urine C-C motif ligand 2, plasma soluble tumor necrosis factor receptors 1 and 2, intercellular adhesion molecule 1 and serum amyloid A). The only adverse event rate that differed between groups was anemia at 32.0% (8/25) for baricitinib 4 mg daily versus 3.7% (1/27) for placebo. Conclusions: Baricitinib decreased albuminuria in participants with Type 2 diabetes and DKD. Further research is required to determine if baricitinib reduces DKD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Self-citationJAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
Self-citationJAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy
Navarro-González, J. F., Mora-Fernández, C., de Fuentes, M. M., & García-Pérez, J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.51 · Cited by 1,072
Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
Afkarian, M., Zelnick, L. R., Hall, Y. N., Heagerty, P. J., Tuttle, K., Weiss, N. S., & de Boer, I. H. (2016) · JAMA · doi:10.1001/jama.2016.10924 · Cited by 1,026
Self-citationDiabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Self-citationBaricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Self-citationEnd-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions
Ritz, E., Rychlík, I., Locatelli, F., & Halimi, S. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70035-1 · Cited by 806
Inflammation and the pathogenesis of diabetic nephropathy
Wada, J., & Makino, H. (2013) · Clinical Science · doi:10.1042/cs20120198 · Cited by 775
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Li, Y., Robinson, B., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Chen, J. T. L., Cope, E., Gipson, D., He, K., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.05.001 · Cited by 656
Transcriptome Analysis of Human Diabetic Kidney Disease
Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., & Susztak, K. (2011) · Diabetes · doi:10.2337/db10-1181 · Cited by 642
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Self-citationPathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
Niewczas, M. A., Gohda, T., Skupien, J., Smiles, A. M., Walker, W. H., Rosetti, F., Cullere, X., Eckfeldt, J. H., Doria, A., Mayadas, T. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060627 · Cited by 485
Fleischmann, R., Schiff, M., van der Heijde, D., Ramos‐Remus, C., Spindler, A., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C., de Bono, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 427
Self-citationDougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Self-citationCirculating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes
Gohda, T., Niewczas, M. A., Ficociello, L. H., Walker, W. H., Skupien, J., Rosetti, F., Cullere, X., Johnson, A. C., Crabtree, G., Smiles, A. M., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060628 · Cited by 356
The epidemiology of chronic kidney disease
Atkins, R. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09403.x · Cited by 320
Berthier, C. C., Zhang, H., Schin, M., Henger, A., Nelson, R. G., Yee, B., Boucherot, A., Neusser, M. A., Cohen, C. D., Carter-Su, C., et al. (2009) · Diabetes · doi:10.2337/db08-1328 · Cited by 317
Self-citationPichler, R., Afkarian, M., Dieter, B. P., & Tuttle, K. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2016 · Cited by 295
Self-citationde Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H. J. L., & Schall, T. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00261-2 · Cited by 273
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Self-citationVaidya, V. S., Niewczas, M. A., Ficociello, L. H., Johnson, A. C., Collings, F. B., Warram, J. H., Krolewski, A. S., & Bonventre, J. V. (2011) · Kidney International · doi:10.1038/ki.2010.404 · Cited by 234
Role of the JAK/STAT signaling pathway in diabetic nephropathy
Marrero, M. B., Banes-Berceli, A. K., Stern, D. M., & Eaton, D. C. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00181.2005 · Cited by 219
Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Więcek, A., Haller, H., & for the Emapticap Study Group (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv459 · Cited by 201
Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., & Krumholz, H. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.18.1930 · Cited by 184
Kremer, J. M., Emery, P., Camp, H. S., Friedman, A., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S., & Keystone, E. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39801 · Cited by 182
Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics
Wolkow, P. P., Niewczas, M. A., Perkins, B., Ficociello, L. H., Lipinski, B., Warram, J. H., & Krolewski, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050556 · Cited by 155 · cited 1×
“Although most of these are systemic cytokines, CCL2 (MCP-1) and CXCL10 (IP-10) were measured in urine, and urinary biomarkers appear to more closely track with inflammation in the kidney than systemic inflammation [44].”
BackgroundPrediction versus aetiology: common pitfalls and how to avoid them
van Diepen, M., Ramspek, C. L., Jager, K. J., Zoccali, C., & Dekker, F. W. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw459 · Cited by 127
JAK inhibition and progressive kidney disease
Brosius, F. C., & He, C. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000079 · Cited by 124
Self-citationTitan, S., Vieira, J. M., Dominguez, W. V., Moreira, S. R. S., Pereira, A. B., Barros, R. T., & Zatz, R. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.06.006 · Cited by 111
Epidemiology and Risk Factors for Chronic Kidney Disease
McClellan, W. M. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.11.006 · Cited by 109
Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
de Boer, I. H., Afkarian, M., Rue, T. C., Cleary, P. A., Lachin, J. M., Molitch, M. E., Steffes, M. W., Sun, W., & Zinman, B. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013091004 · Cited by 108
Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice
Zhang, H., Nair, V., Saha, J., Atkins, K. B., Hodgin, J. B., Saunders, T. L., Myers, M. G., Werner, T. B., Kretzler, M., & Brosius, F. C. (2017) · Kidney International · doi:10.1016/j.kint.2017.03.027 · Cited by 107
Self-citationKramer, A., Pippias, M., Stel, V. S., Bonthuis, M., Díez, J. M. A., Afentakis, N., de la Torre, R. A., Ambühl, P. M., Bikbov, B. T., Caamaño, E. B., et al. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfv151 · Cited by 96
Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD
Szczech, L. A. M., & Lazar, I. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09002.x · Cited by 94
Serum amyloid A and inflammation in diabetic kidney disease and podocytes
Anderberg, R. J., Meek, R. L., Hudkins, K. L., Cooney, S. K., Alpers, C. E., LeBoeuf, R. C., & Tuttle, K. R. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.163 · Cited by 87
Self-citationTherapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches
Abdel‐Rahman, E. M., Saadulla, L., Reeves, W. B., & Awad, A. S. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1912-5 · Cited by 63
Choudhury, G. G., Ghosh‐Choudhury, N., & Abboud, H. E. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1044 · Cited by 57
Chronic kidney disease: Stemming the global tide
Nwankwo, E., Bello, A. K., & Nahas, A. M. E. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.09.005 · Cited by 47
Filgotinib for the treatment of rheumatoid arthritis
Taylor, P. C., Azeez, M., & Kiriakidis, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1372422 · Cited by 41
Potential roles of erythropoietin in the management of anaemia and other complications diabetes
Khoshdel, A., Carney, S. L., Gillies, A. H. B., Mourad, A., Jones, B. F., Nanra, R. S., & Trevillian, P. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00711.x · Cited by 28
Chronic Kidney Disease—A Challenge for All Ages
de Boer, I. H. (2012) · JAMA · doi:10.1001/jama.2012.30761 · Cited by 24
New approaches to the treatment of nephropathy in diabetes
Thomas, M. C., & Groop, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.591785 · Cited by 17
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Metabolic Inflammation and Insulin Resistance in Obesity
Wu, H., & Ballantyne, C. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.315896 · Cited by 1,059
Macrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Metadata
- Authors
- Tuttle, K. R., Brosius, F. C., Adler, S. G., Kretzler, M., Mehta, R. L., Tumlin, J. A., Tanaka, Y., Haneda, M., Liu, J., Silk, M. E., Cardillo, T. E., Duffin, K. L., Haas, J. V., Macias, W. L., Nunes, F. P., & Janes, J. M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-22
- Volume
- 33
- Issue
- 11
- Pages
- 1950-1959
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2790867818
- Cited by
- 284
- References
- 59
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.